Review Article

Can α-Lipoic Acid Mitigate Progression of Aging-Related Decline Caused by Oxidative Stress?

Authors: Maharsh K. Patel, MD, Mary Anne Riley, MS, Stephen Hobbs, PhD, Miriam Cortez-Cooper, PT, PhD, Vincent J.B. Robinson, MD

Abstract

Aging is progressively deteriorating physiological function that leads to increasing risks of illness and death. Increases in life expectancy and the aging of a large segment of the population have made age-related disability and morbidity increasingly important issues. Supplements such as α-lipoic acid may have antiaging effects by positively affecting oxidative stress, cognitive function, and cardiovascular function.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Janker J, Geerlings M, Schmand B. Are memory complaints predicitive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 2000;15: 983-991.
 
1a. Sawabe M. Vascular aging: from molecular mechanism to clinical significance. Geriatr Gerontol Int 2010;10(Suppl 1): S213-S220.
 
2. Finch CE, Tanzi RE. Genetics of aging. Science 1997;278:407-411.
 
3. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1957;2:298-300.
 
4. Terman A, Brunk UT. Oxidative stress, accumulation of biological garbage, and aging. Antioxid Redox Signal 2006;1:197-204.
 
5. Malinin NL, West XZ, Byzova TV. Oxidation as ‘‘the stress of life.’’ Aging (Albany NY) 2011;3:906-910.
 
6. Hekimi S, Lapointe J, Wen Y. Taking a ‘‘good’’ look at free radicals in the aging process. Trends Cell Biol 2011;21:569-576.
 
7. Venkataraman K, Khurana S, Tai TC. Oxidative stress in aging Y matters of the heart and mind. Int J Mol Sci 2013;14:17897-925.
 
8. Malhotra JD, Miao H, Zhang K, et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. PNAS 2008;105:18525-18530.
 
9. Martin GM. Genetics and the pathobiology of ageing. Philos Trans R Soc Lond B Biol Sci 1997;352:1773-1780.
 
10. Martin GM, Austad SN, Johnson TE. Genetic analysis of ageing: role of oxidative damage and environmental stresses. Nat Genet 1996;13:25-34.
 
11. Humphries KM, Szweda PA, Szweda LI. Aging: a shift from redox regulation to oxidative damage. Free Radic Res 2006;40:1239-1243.
 
12. Islam MT. Anxioxidant activities of dithiol alpha-lipoic acid. Bangladesh J Med Sci 2009;8:1-5.
 
13. Singh U, Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutr Rev 2008;66:646-657.
 
14. Huang EA, Gitelman SE. The effect of alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2008;9:69-73.
 
15. Evans JL, Heymann CJ, Goldfine ID, et al. Pharmacokinetics tolerability, and fructosamine-lowering effect of a novel, controlled release formulation of alpha-lipoic acid. Endocr Pract 2002;8:29-35.
 
16. Gulliams T. Time-Release Lipoic Acid: More Marketing than Data. Stevens Point, WI: Point Institute; 2007: pp 1-6.
 
17. Farr SA, Poon HF, Dogrukol-Ak D, et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003;84:1173-1183.
 
18. Lovell MA, Xie C, Xiong S, et al. (2003). Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha-lipoic acid. J Alzheimers Dis 2003;5:229-239.
 
19. Cummings BP, Stanhope KL, Graham JL, et al. Dietary fructose accelerates the development of diabetes in UCD-T2DM rats: amelioration by the antioxidant, alpha-lipoic acid. Am J Physiol Regul Integr Comp Physiol 2010;298:R1343-R1350.
 
20. Maczurek A, Hager K, Kenklies M, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease. Adv Drug Deliv Rev 2008;60:1463-1470.
 
21. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997;20:369-373.
 
22. Heitzer T, Finckh B, Albers S, et al. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001;31:53-61.
 
23. Serbinova E, Khwaja S, Reznick AZ, et al. Thioctic acid protects against ischemia-reperfusion injury in the isolated perfused Langendorff heart. Free Radic Res Commun 1992;17:49-58.
 
24. Bae EH, Lee KS, Lee J, et al. Effects of alpha-lipoic acid on ischemia-reperfusion-induced renal dysfunction in rats. Am J Physiol Renal Physiol 2008;294:F272-F280.
 
25. Vasdev S, Gill V, Longerich L, et al. Salt-induced hypertension in WKY rats: prevention by alpha-lipoic acid supplementation. Mol Cell Biochem 2003;254:319-326.
 
26. Vasdev S, Gill V, Parai S, et al. Dietary lipoic acid supplementation attenuates hypertension in Dahl salt sensitive rats. Mol Cell Biochem 2005;275:135-141.
 
27. Hoffman MA, Tritschler HJ, Bierhaus A, et al. Lipoate effects on atherogenesis. In: Fuchs J, Packer L, Zimmer G, eds. Lipoic Acid in Health and Disease. New York: Marcel Dekker; 2000: pp 321-336.
 
28. Tardif J-C, Bourassa MG, eds. Developments in Cardiovascular Medicine: Antioxidants and Cardiovascular Disease. Vol 233 Amsterdam: Kluwer Academic Press; 2000.
 
29. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-1456.
 
30. Kagan W, Kuklinski B, Ruhlmann C, et al. Recycling of vitamin E in human low density lipoproteins. J Lipid Res 1992;33:385-397 [Abstract] .
 
31. Angelucci L, Mascitelli-Coriandoli E. Anticholesterol activity of alpha-lipoic acid. Nature 1958;181:911-912.
 
32. Ivanov VN. Effect of lipoic acid on tissue respiration in rabbits with experimental atherosclerosis. Cor Vasa 1974;16:141-150.
 
33. Shih JC. Atherosclerosis in Japanese quail and the effect of lipoic acid. Fed Proc 1983;42:2494-2497.
 
34. Ford I, Cotter MA, Cameron NE, et al. The effects of treatment with α-lipoic acid or evening primrose oil on vascular haemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Metabolism 2001;50:868-875.
 
35. Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med 1999;26:1495-1500.
 
36. Androne L, Gavan NA, Veresiu IA, et al. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000;14:327-330.
 
37. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study). Diabetologia 1995;38:1425-1433.
 
38. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997;46(Suppl 2):S62-S66.
 
39. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006;11:294-329.
 
40. Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26:770-776.
 
41. Tankova T, Koev D, Dakovska L. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). Rom J Intern Med 2004;42:457-464.
 
42. Shenk J, Liu J, Fischbach K, et al. The effect of acetyl-L-carnitine and lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer’s disease. J Neurol Sci 2009;283:199-206.
 
43. Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013;368:1489-1497.
 
44. Kim KM, Jung BH, Paeng KJ, et al. Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer’s disease. Brain Res Bull 2004;64:47-51.
 
45. Montine TJ, Markesbery WR, Morrow JD, et al. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer’s disease. Ann Neurol 1998;44:410-413.
 
46. Department of Veterans Affairs/Oregon Health and Science University. Prevention of Cisplatin Ototoxicity with the Antioxidant Alpha-Lipoic Acid. clinicaltrials.gov identifier NCT00477607. 2011.
 
47. Emory University Hospital and Grady Health System. CVD Risk and Prevention in Early Glucose Intolerance. clinicaltrials.gov identifier NCT00122447. 2012.